医学
初级保健
2型糖尿病
连续血糖监测
内科学
胰岛素
糖尿病
重症监护医学
内分泌学
滴定法
血糖自我监测
2型糖尿病
胰腺激素
作者
Ramzi Ajjan,Tadej Battelino,Xavier Cos,Stefano Del Prato,Chantal Mathieu,Mohammed S. Almehthel,Jochen Seufert,Bruno Guerci,Samuel Seidu
出处
期刊:
[Elsevier BV]
日期:2026-08-01
卷期号:2 (8): 100193-100193
标识
DOI:10.1016/j.lanprc.2026.100193
摘要
The global burden of diabetes is projected to reach 1·31 billion people by 2050, the majority of whom will have type 2 diabetes (T2D). There are considerable regional and socioeconomic inequities in access to care for people with T2D, and providing care for such a large number of individuals will require changes to current management approaches. Chronic hyperglycaemia directly contributes to premature morbidity and mortality while impairing quality of life. Therefore, timely intervention to improve hyperglycaemia will reduce long-term complications and spiralling diabetes health-care costs. However, treatment inertia is common, particularly with insulin initiation and titration, related to the complexities involved and concerns over hypoglycaemia. This inertia is particularly true for people with T2D managed in primary health care. The increasing use of continuous glucose monitoring (CGM) systems has enabled more effective management of individuals with diabetes, including timely initiation and titration of insulin therapy for people with T2D, typically started as basal insulin. As CGM metrics can safely and effectively guide health-care professionals and individuals with diabetes to refine insulin treatment, practical guidance on how to best apply this information in clinical practice is needed. In this Viewpoint, we propose practical algorithms for using well established CGM metrics in the management of basal-insulin initiation, titration, and intensification, as well as in the process of insulin deintensification. The collective aim of this expert guidance is to optimise glycaemia by not only lowering high glucose levels, but also minimising hypoglycaemia to improve outcomes and quality of life for individuals with T2D.
科研通智能强力驱动
Strongly Powered by AbleSci AI